Novo Nordisk’s zenagamtide shows significant HbA1C reductions

8 June 2026

Danish pharma major Novo Nordisk (NOV: N) announced new clinical data from the positive Phase II trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.

Presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, on Saturday, results from the Phase II dose finding study included the evaluation of six subcutaneous doses of zenagamtide (ranging from 0.4mg to 40mg) versus matched placebo in 262 adults with type 2 diabetes inadequately controlled (HbA1C 7.0–10.0%) on metformin, with or without an SGLT2 inhibitor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK